<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39426501</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-6551</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>17</Day></PubDate></JournalIssue><Title>Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology</Title><ISOAbbreviation>J Nucl Cardiol</ISOAbbreviation></Journal><ArticleTitle>Fast vs slow rubidium-82 infusion profiles and test-retest precision of myocardial perfusion using contemporary 3D cardiac analog PET-CT imaging.</ArticleTitle><Pagination><StartPage>102059</StartPage><MedlinePgn>102059</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nuclcard.2024.102059</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1071-3581(24)00752-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">On legacy 2D PET systems utilizing a 50 mL/min Rb-82 profile, test-retest precision of quantitative perfusion is ∼10%. It is unclear whether Rb-82 infusion rate significantly impacts quantitative perfusion and/or image quality on modern analog 3D PET-CT systems. We aimed to determine whether the Rb-82 infusion profile significantly impacts test-retest precision of quantitative perfusion, perfusion metrics, and/or image quality on a modern analog 3D PET-CT scanner.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Ninety-eight volunteers from 3 distinct groups: healthy volunteers (Normals), patients with risk factors and/or coronary disease (Clinicals) and patients with prior transmural myocardial infarctions (Infarcts), underwent cardiac stress testing on an analog 3D PET-CT. Participants received 3 consecutive resting scans and 2 consecutive stress scans, minutes apart, with two randomly assigned Rb-82 infusion profiles: 50 mL/min (fast [F]) and 20 mL/min (slow [S]). Perfusion metrics (resting (rMBF) and stress myocardial blood flow (sMBF)) were calculated using HeartSee software. Coefficients of variance (COV), repeatability (RC), MBF and image quality metrics were compared.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">rMBF correlated well between F and S profiles, with intraclass correlation coefficients (ICC) ranging 0.91-0.93. sMBF was highly correlated between F and S profiles (ICC=0.97). Fast and slow profiles were associated with similar same-day test-retest precision (COV 11.5% vs. 11.3% (p=0.77); RC 21.5% vs. 22.6%, for F-F vs S-S). There were no clinically significant differences in MBF values between F and S profiles. Image quality metrics were similar between the 2 profiles.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">There are no clinically significant differences in precision, perfusion metrics or image quality between Rb-82 fast and slow infusions using a contemporary analog 3D PET-CT.</AbstractText><CopyrightInformation>Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bober</LastName><ForeName>Robert M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>John Ochsner Heart and Vascular Institute, Department of Cardiovascular Diseases, 1514 Jefferson Highway, New Orleans, LA 70121-2483 USA; Ochsner Clinical School, Queensland University School of Medicine, New Orleans, LA USA. Electronic address: rbober@ochsner.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milani</LastName><ForeName>Richard V</ForeName><Initials>RV</Initials><AffiliationInfo><Affiliation>Center for Healthcare Innovation, Sutter Health, San Francisco, CA USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abelhad</LastName><ForeName>Nadia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>John Ochsner Heart and Vascular Institute, Department of Cardiovascular Diseases, 1514 Jefferson Highway, New Orleans, LA 70121-2483 USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Velasco-Gonzalez</LastName><ForeName>Cruz</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Ochsner Health, Ochsner Center for Outcomes Research, New Orleans, LA USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>Merrill</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>John Ochsner Heart and Vascular Institute, Department of Cardiovascular Diseases, 1514 Jefferson Highway, New Orleans, LA 70121-2483 USA; Ochsner Clinical School, Queensland University School of Medicine, New Orleans, LA USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morin</LastName><ForeName>Daniel P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>John Ochsner Heart and Vascular Institute, Department of Cardiovascular Diseases, 1514 Jefferson Highway, New Orleans, LA 70121-2483 USA; Ochsner Clinical School, Queensland University School of Medicine, New Orleans, LA USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Nucl Cardiol</MedlineTA><NlmUniqueID>9423534</NlmUniqueID><ISSNLinking>1071-3581</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">3D Positron Emission Tomography (PET)</Keyword><Keyword MajorTopicYN="N">Rb-82 infusion profile</Keyword><Keyword MajorTopicYN="N">image quality</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest ☒ The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Robert Bober, MD reports financial support was provided by Bracco Diagnostics Inc. Robert Bober, MD reports a relationship with CDL Nuclear Technologies that includes: consulting or advisory and speaking and lecture fees. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>20</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>20</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>19</Day><Hour>19</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39426501</ArticleId><ArticleId IdType="doi">10.1016/j.nuclcard.2024.102059</ArticleId><ArticleId IdType="pii">S1071-3581(24)00752-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle>